Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $202.7 million.

  • Iovance Biotherapeutics' Total Liabilities rose 12620.2% to $202.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.7 million, marking a year-over-year increase of 12620.2%. This contributed to the annual value of $200.0 million for FY2024, which is 218.81% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Total Liabilities stood at $202.7 million, which was up 12620.2% from $208.9 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Total Liabilities' 5-year high stood at $208.9 million during Q2 2025, with a 5-year trough of -$773.5 million in Q3 2024.
  • Moreover, its 3-year median value for Total Liabilities was $189.8 million (2024), whereas its average is $15.4 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Total Liabilities crashed by 53377.71% in 2024, and later skyrocketed by 12718.78% in 2025.
  • Iovance Biotherapeutics' Total Liabilities (Quarter) stood at $195.7 million in 2023, then grew by 2.19% to $200.0 million in 2024, then rose by 1.32% to $202.7 million in 2025.
  • Its Total Liabilities was $202.7 million in Q3 2025, compared to $208.9 million in Q2 2025 and $198.9 million in Q1 2025.